RE:RE:RE:RE:CYDY Their efficacy results came with a price which was severe adverse effects at high dosage so the market didn't like it thus their SP got beat. If the safety is compromised no matter how good the efficacy is it won't matter! Now they most likely won't be able to carry on with those high dosings going forward would their drug still be effective at lower dosage?It shows how important a safe yet effective MTD is.Hopefully THTX 's PDC shows efficacy at safe and tolerated dosages.
jfm1330 wrote: The oddity is Cytodyn, not Thera. If Thera get excellent results in oncology and the SP barely moves, than I will blame the management for not being able to sell a real good story. At this point, oncology is hope of a good story based on educated guesses by us, but this is not a confirmed fact. Possibility of failure or mild results is there. And again, I looked at Sutro, and even with good efficacy data on humans, their valuation is not very high. So even with some proof of efficacy, the SP will not go crazy. It should rise, maybe double, but not more than that unless results would be really spectacular.
SPCEO1 wrote: Even with the inevitable happening to CYDY (and still in the process of happening - how much longer before their CEO flees the country I wonder), it still has a market cap of $463 million versus TH's $274 million. So, despite the insanity at CYDY, investors somehow value it more highly than TH. Life is weird - very, very weird!
jfm1330 wrote: 0.70$ today, less than a year ago it was at 7.15$. So much for "promotion" I guess...